In the scope of the World Antibiotic Awareness Week 2018, Bpifrance (French Public Investment Bank) has highlighted the French key…
Mobidiag announced today that it has received the final €4M tranche of a €15M three-year project secured by the Company…
The article features the successful evaluation by the Leicester Royal Infirmary of Amplidiag® Easy, the automated solution for routine diagnostic…
Mobidiag will hold a new symposium at the 38ème Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse in Paris, France. Register now! Mobidiag…
The article focuses on Novodiag® solution, the automated molecular diagnostic system allowing rapid and reliable results directly from patient sample.…
Released in 2016 for the detection of most relevant carbapenemase groups as well as vancomycin resistance markers from pure culture…
Mobidiag Ltd., a Finnish molecular diagnostics company, announced today that it has initiated the development of a sepsis assay on…
Mobidiag has successfully completed a 4 million euros funding supported by the Finnish investment service company Springvest Oy (former Kansalaisrahoitus)…
CE-IVD marking of Amplidiag® CarbaR+MCR, a molecular test allowing detection of the main carbapenemase-producing organisms and colistin resistance markers in…
New molecular diagnostic test for the simultaneous detection of most common enteric pathogens directly from stool samples. Espoo, Finland, April…